Pre-emptive hydrocortisone therapy in early septic shock: a double-blind, allocation-concealed, pilot randomized...

Area of Science:

• Critical Care Medicine
• Pharmacology
• Emergency Medicine

Background:

• Sepsis is a leading cause of global mortality, often progressing to septic shock.
• Low-dose corticosteroids, including hydrocortisone, show potential in managing septic shock.
• The efficacy of pre-emptive hydrocortisone in early septic shock requires further investigation.

Purpose of the Study:

• To evaluate the impact of pre-emptive low-dose, short-course hydrocortisone on patient outcomes in early septic shock.
• To determine if early hydrocortisone administration influences vasopressor requirements and other critical care metrics.

Main Methods:

• A double-blind, randomized controlled trial design was employed.
• Patients with early septic shock were randomized to receive either pre-emptive hydrocortisone or usual care.
• The primary endpoint was the requirement for vasopressor therapy.

Main Results:

• Pre-emptive hydrocortisone significantly decreased vasopressor therapy duration and cumulative dose.
• Mechanical ventilation necessity was substantially lower in the hydrocortisone group (10% vs. 40%).
• No significant differences were found in mortality, SOFA scores, or ICU length of stay.

Conclusions:

• Pre-emptive low-dose hydrocortisone effectively reduced vasopressor support and mechanical ventilation needs in early septic shock.
• The treatment did not alter the progression to established septic shock but improved hemodynamic management.
• Hydrocortisone was associated with a favorable safety profile, with comparable adverse events to usual care.